About this trial
The goal of this registry is to better understand how primary biliary cholangitis develops over time, including the role of disease-related biomarkers, complications of the disease, and symptom burden. Patients with primary biliary cholangitis treated at participating centres in Austria will be invited to take part in this prospective registry. Participation in an associated biobank is optional. Clinical and laboratory data will be collected, and patients will be followed regularly through scheduled clinic visits. In addition, biological samples (serum, plasma, and, if available, liver tissue) may be collected and stored in the biobank for future research.
Eligibility criteria
Qualifiers
Age >18 years
Confirmed diagnosis of primary biliary cholangitis (at least two of the following three criteria must be fulfilled: persistent elevation of alkaline phosphatase above the upper limit of normal for at least 6 months; presence of antimitochondrial antibodies or PBC-specific antinuclear antibodies; characteristic histopathology)
Written informed consent for participation in the registry
Disqualifiers
Withdrawal of written informed consent
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Medical University of Vienna
Lead sponsor
Klinik Ottakring
Collaborator
Medical University of Graz
Collaborator
Salzburger Universitätsklinkum
Collaborator
Universitätsklinikum St. Pölten
Collaborator
Kepler University Hospital
Collaborator
Klinikum Klagenfurt am Wörthersee
Collaborator
Klinikum Wels-Grieskirchen
Collaborator
Medical University Innsbruck
Collaborator
Ordensklinikum Linz GmbH Krankenhaus Barmherzige Schwestern
Collaborator
Krankenanstalt Rudolfstiftung
Collaborator